Akciğer Kanserinde Sağkalım ve Evre

Year 2023, Volume: 7 Issue: 2, 219 - 224, 07.08.2023

Kubilay İnan , Merve Şengül İnan , İlknur Aytekin Çelik , Ozgur Omer Yildiz , Nurettin Karaoglanoglu

https://doi.org/10.46332/aemj.1183432

Abstract

Amaç: Akciğer kanseri, dünya çapında kanser ölümlerinin önde gelen nedenidir. Küçük hücreli dışı akciğer kanseri (KHDAK) için 5 yıllık sağkalım oranları %20 ile %70 arasında değişmektedir.

Bu çalışmada KHDAK nedeniyle opere edilen toplam 83 hastada erken nüks oranları araştırılmakta ve literatürdeki veriler ışığın-da ilgili bulgular sunulmaktadır.
Araçlar ve Yöntem: Mart 2019-Eylül 2021 tarihleri arasında malignite nedeniyle akciğer rezeksiyonu yapılan hastalar retrospek-tif olarak incelendi. Yaş, cinsiyet, ameliyat öncesi kemoterapi uygulamasının varlığı, yapılan ameliyatlar, ameliyat tarihleri, patoloji sonuçları, ameliyat sonrası evreleme, sağkalım ve nüksleri içeren hasta verileri belgelendi.

Bulgular: Mart 2019 ile Eylül 2021 arasında malignite nedeniyle akciğer rezeksiyonu yapılan toplam 83 hasta incelendi. Has-taların medyan yaşı 62 idi. Toplam 4 hastada nüks gelişti ve 79'u nüks olmadan takiplerine devam etti. Akciğer rezeksiyonu yapılan hastaların sekizi (%9.6) postoperatif ilk 2 yıllık dönemde kaybedildi. Bu sekiz hastanın ortalama sağkalım süresi 14.6 ay (7-20 ay) idi.

Sonuç: Yaş, cinsiyet, patolojik tip, tümörün yerleşim yeri gibi çeşitli parametreler incelenip karşılaştırılsa da cerrahi uygulanan hastaların uzun dönem sağkalımlarını etkileyen asıl parametrenin tümörün evresi olduğu bilinmektedir.

Keywords

Cerrahi, Göğüs Cerrahisi, Malignite, Kanser

Supporting Institution

Destekleyen Kurum YOK

Project Number

PROJE ÇALIŞMASI DEĞİL

Survival and Stage in Lung Cancer

Abstract

Purpose: Lung cancer is the leading cause of cancer death worldwide. Although the 5-year survival rates of for non-small cell lung carcinoma (NSCLC) ranges from 20% to 70%. The present study investigates the rates of early recurrence in a total of 83 patients operated for NSCLC and presents the related findings in reference to the data available in the literature.

Materials and Methods: Patients who underwent lung resection for malignancy between March 2019 and September 2021 were retrospectively examined. The patient data, including age, gender, presence of preoperative chemotherapy administration, opera-tions performed, operation dates, pathology results, postoperative staging, survival, and relapses, were documented.

Results: A total of 83 patients who underwent lung resection for malignancy between March 2019 and September 2021 were examined. The patients had a median age of 62 years. Of the total number of patients four patients developed recurrence and 79 continued their follow-up without any recurrence. Of the patients who underwent lung resection, eight (9.6%) patients died within the first postoperative 2-year period. The mean survival period of these eight patients was 14.6 months (7–20 months).

Conclusion: Although various parameters, such as age, gender, pathological type, and location of the tumor are examined and compared, according to the available data on the long-term survival of surgical patients, it is known that the only parameter that affects survival is the pathological stage of the patient.

Keywords

Cancer, Malignancy, Surgery, Thoracic Surgery

Project Number

PROJE ÇALIŞMASI DEĞİL

References

• 1. Allemani C, Weir HK, Carreira H. et al. CON-CORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individu-al data for 25.676.887 patients from 279 popula-tion-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977-1010.
• 2. Martin J, Ginsberg RJ, Venkatraman ES. et al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol. 2002;20(8):1989-1995.
• 3. Taylor MD, Nagji AS, Bhamidipati CM. et al. Tumor recurrence after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2012;93(6):1813-1821.
• 4. Gourcerol D, Scherpereel A, Debeugny S. et al. Relevance of an extensive follow-up after sur-gery for nonsmall cell lung cancer. Eur Respir J. 2013;42(5):1357-1364.
• 5. Endo C, Sakurada A, Notsuda H. et al. Results of long-term follow-up of patients with completely resected non-small cell lung cancer. Ann Thorac Surg. 2012;93(4):1061-1068.
• 6. Westeel V, Choma D, Clément F. et al. Relevance of an intensive postoperative follow-up after sur-gery for non-small cell lung cancer. Ann Thorac Surg. 2000;70(4):1185-1190.
• 7. Yue D, Gong L, You J et al. Survival analysis of patients with non-small cell lung cancer who un-derwent surgical resection following 4 lung can-cer resection guidelines. BMC Cancer. 2014;14:422.
• 8. Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer Epidemiol Bi-omarkers Prev. 2019;28(10):1563-1579.
• 9. Mehta HJ, Ross C, Silvestri GA. et al. Evaluation and treatment of high-risk patients with early-stage lung cancer. Clin Chest Med. 2011;32(4):783-797.
• 10. Vest MT, Herrin J, Soulos PR. et al. Use of new treatment modalities for non-small cell lung can-cer care in the Medicare population. Chest. 2013;143(2):429-435.
• 11. Scott WJ, Howington J, Feigenberg S. et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical prac-tice guidelines. 2nd ed. Chest. 2007;132(3):234-242.
• 12. Kratzke R, Franklin MJ. Lung cancer epidemiolo-gy. Schwab M, ed.: Encyclopedia of Cancer. Ber-lin, Germany: Springer; 2011:2100-2104.
• 13. Kocher F, Hilbe W, Seeber A. et al. Longitudinal analysis of 2293 NSCLC patients: a comprehen-sive study from the TYROL registry. Lung Can-cer. 2015;87(2):193-200.
• 14. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623-1640.
• 15. Travis WD, Brambilla E, Burke AP. et al. Intro-duction to the 2015 World Health Organization classification of tumors of the lung, pleura, thy-mus, and heart. J Thorac Oncol. 2015;10(9):1240-1242.
• 16. Pardoll DM. The blockade of immune check-points in cancer immunotherapy. Nat Rev Can-cer. 2012;12(4): 252-264.
• 17. Gilligan D, Nicolson M, Smith I. et al. Preopera-tive chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre ran-domised trial and update of systematic review. Lancet. 2007;369(9577): 1929-1937.
• 18. Felip E, Rosell R, Maestre JA. et al. Spanish Lung Cancer Group. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemother-apy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010;28(19):3138-3145.
• 19. Khullar OV, Liu Y, Gillespie T. et al. Survival After Sublobar Resection versus Lobectomy for Clinical Stage IA Lung Cancer: An Analysis from the National Cancer Data Base. J Thorac Oncol. 2015;10(11):1625-1633.
• 20. Billmeier SE, Ayanian JZ, Zaslavsky AM. et al. Predictors and outcomes of limited resection for early-stage non-small cell lung cancer. J Natl Cancer Inst. 2011;103(21):1621-1629.
• 21. Kodama K, Higashiyama M, Okami J. et al. On-cologic Outcomes of Segmentectomy Versus Lo-bectomy for Clinical T1a N0 M0 Non-Small Cell Lung Cancer. Ann Thorac Surg. 2016;101(2):504-511.
• 22. Kodama K, Doi O, Higashiyama M. et al. Inten-tional limited resection for selected patients with T1 N0 M0 non-small-cell lung cancer: a single-institution study. J Thorac Cardiovasc Surg. 1997;114(3):347-353.
• 23. İnan, K., İnan, M. Ş., Bıçakçıoğlu, P. et al. The surgical management in pneumonectomy cases for lung cancer treatment. Curr Thorac Surg. 2020;5(2):64-70.
• 24. Ferguson MK, Karrison T. Does pneumonecto-my for lung cancer adversely influence long-term survival? J Thorac Cardiovasc Surg. 2000;119(3):440-448.